Cargando…
A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer
BACKGROUND: This multicentre randomised phase III trial was designed to determine whether adjuvant chemotherapy with gemcitabine improves the outcomes of patients with resected pancreatic cancer. METHODS: Eligibility criteria included macroscopically curative resection of invasive ductal carcinoma o...
Autores principales: | Ueno, H, Kosuge, T, Matsuyama, Y, Yamamoto, J, Nakao, A, Egawa, S, Doi, R, Monden, M, Hatori, T, Tanaka, M, Shimada, M, Kanemitsu, K |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2743365/ https://www.ncbi.nlm.nih.gov/pubmed/19690548 http://dx.doi.org/10.1038/sj.bjc.6605256 |
Ejemplares similares
-
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
por: Heinrich, Stefan, et al.
Publicado: (2011) -
Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy
por: Matsui, Hiroto, et al.
Publicado: (2017) -
Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study
por: Ueno, Makoto, et al.
Publicado: (2021) -
Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
por: Hagiwara, Yasuhiro, et al.
Publicado: (2017) -
Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant chemotherapy
por: Aoyama, Toru, et al.
Publicado: (2017)